News

Filter

Current filters:

Depomed

1 to 9 of 28 results

Depomed wins in law suit seeking FDA orphan drug exclusivity for Gralise

Depomed wins in law suit seeking FDA orphan drug exclusivity for Gralise

07-09-2014

US specialty drugmaker Depomed says that Judge Kentaji Brown Jackson of the federal district court for…

DepomedGraliseLegalNeurologicalPharmaceuticalRare diseasesUSA

Mallinckrodt’s MNK-155 shows efficacy in Ph III acute pain trial

Mallinckrodt’s MNK-155 shows efficacy in Ph III acute pain trial

05-09-2014

US drugmaker Mallinckrodt reported that a Phase III efficacy trial of investigational MNK-155 met the…

AcuformDepomedMallinckrodtMNK-155NeurologicalPharmaceuticalResearch

Depomed prevails in Gralise ANDA litigation with Actavis

Depomed prevails in Gralise ANDA litigation with Actavis

20-08-2014

US drug maker Depomed saw its shares climb more than 12% to $14.76 on Tuesday, on the news that the firm…

ActavisDepomedGraliseLegalNeurologicalPatentsPharmaceuticalUSA

US court preliminary order to prevent Actavis launch of generic Gralise

US court preliminary order to prevent Actavis launch of generic Gralise

18-07-2014

Judge Joel Pisano of the US District Court for the District of New Jersey has entered an order preliminarily…

ActavisActavis Elizabeth LLCAnticonvulsantsDepomedGenericsGraliseHealth Medical PharmaLaw CrimeLegalNeurologicalPatentsPfizerUSA

Depomed settlements with two Gralise ANDA filers

15-04-2014

US specialty drugmaker Depomed has entered into settlement agreements with two of the three defendants…

DepomedGenericsGraliseIncepta PharmaceuticalsLegalNeurologicalNorth AmericaPatentsUSAZydus Cadila

Mallinckrodt gains FDA approval for Xartemis XR

Mallinckrodt gains FDA approval for Xartemis XR

12-03-2014

The US Food and Drug Administration has approved Ireland-headquartered specially drugmaker Mallinckrodt’s…

DepomedMallinckrodtNeurologicalNorth AmericaPharmaceuticalRegulationUSAXartemis XR

PDL BioPharma secures royalties on diabetes products in $240m deal

PDL BioPharma secures royalties on diabetes products in $240m deal

22-10-2013

PDL BioPharma has acquired the rights to receive royalties and milestones payable on sales of Type 2…

DepomedDiabetesFinancialGlumetzaInvokanaJanumetLicensingmetforminNorth AmericaPDL BioPharmaPharmaceutical

Depomed expands geographic scope of metformin deal with Merck

10-09-2013

USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license…

DepomedDiabetesJanumetLicensingMerck & CometforminPharmaceutical

1 to 9 of 28 results

COMPANY SPOTLIGHT

Menarini

Back to top